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Abstract: Stress-induced hyperglycaemia is 
prevalent in critical care. Tight glucose control can 
reduce mortality up to 43%. An adaptive control 
algorithm utilising insulin and nutritional feed 
inputs for targeted glycaemic control in critically ill 
patients is presented. Validation is performed using 
retrospective patient data (n=19) in simulated 
glucoregulatory trials. Conventional sliding-scale 
and insulin-only methods are compared. Results 
show a reduction in mean glucose levels, and 
variability. A 312% increase in time spent in the 4-
6mmol/L normal glucose band compared to sliding-
scale and a 240% increase compared to the insulin-
only protocol is reported. Results are obtained using 
60% more insulin and 20% more nutrition across a 
wide cross-section of ICU patients and patient 
condition, indicating that the timing of control input 
administration is more crucial than their absolute 
amounts. The results show potential in reducing ICU 
mortality and the risk of severe complications.  
 
 
Introduction 
 
Critically ill patients often experience stress-induced 
hyperglycaemia, even with no prior diabetes [1, 2]. 
Hyperglycaemia worsens outcomes, increasing risk of 
severe infection, myocardial infarction, neuropathy, and 
multiple organ failure [1]. Tight glucose control can 
reduce mortality by up to 45% [1, 2].  
Insulin-mediated glycaemic control, however, is 
severely challenged in critical care where effective 
insulin resistance is usually elevated [3, 4]. In addition, 
insulin effect saturates at high concentrations [5], 
limiting the achievable glycaemic reduction. Studies 
also indicate that high glucose nutritional regimes often 
result in excess glucose [6], which exacerbates 
hyperglycaemia. Research with lower glucose nutrition 
alone in critical care has seen significant reductions in 
glucose levels [7]. This research incorporates exogenous 
nutritional input modulation into the insulin-based 
adaptive control algorithm developed in [8].  
 
Materials and Methods 
 
Chase et al. [8] used an extended system model that 
captured rate of insulin utilisation, insulin losses and 
saturation dynamics, and is also used in this study: 
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where G(t) [mmol/L] is the plasma glucose above an 
equilibrium level, GE [mmol/L]. I(t) [mmol/L] is plasma 
insulin concentration resulting from exogenous insulin 
input, uex(t) [mU/min]. Q(t) [mU/L] is interstitial insulin 
concentration and k [1/min] accounts for the effective 
life of insulin in the system. Patient endogenous glucose 
clearance and insulin sensitivity are pG [1/min] and SI 
[L/(mU.min)], respectively. V [L] is the insulin 
distribution volume and n [1/min] is the constant first 
order decay rate for insulin from plasma.  Total plasma 
glucose input is denoted P(t) [mmol/(L.min)]. kpr is the 
rise rate of rate of plasma glucose input from enterally 
administered feed [1/min]. kpd  is the decay rate of rate 
of glucose input into plasma from enterally 
administered feed [1/min]. iP , 1+iP  are stepwise 
consecutive enteral glucose feed rates [mmol/L.min]. 
Michaelis-Menten functions are used to model 
saturation, with αI [L/mU] used for the saturation of 
plasma insulin disappearance, and αG [L/mU] for the 
saturation of insulin-dependent glucose clearance. In 
this research, k, n, αG, αI and V are a priori identified 
from generic population values [8].   
In this study, non-steady stepwise enteral glucose 
fluxes are employed for control and modelled using the 
2-compartment model in Eqs. (4-5). The exponential 
rates for total glucose rate of appearance (GRa) rise (kpr) 
and decay (kpd) can model, simply, the effect of transient 
net hepatic glucose output and glucose disposal. 
Impaired splanchnic and peripheral glucose uptake in 
diabetes and stress-induced hyperglycaemia imply a 
slow decay rate in total GRa following nutritional feed 
reduction [9, 10]. Conversely, the rate of peripheral 
appearance of oral glucose is approximately equal to the 
intestinal absorption rate, which implies a rapid rise in 
total GRa following a nutritional feed increase [11].  
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Thus, kpr and kpd are set to 0.0347min-1 and 0.0068min-1 
corresponding to half-lives of 20 and 100mins to reflect 
this published data.   
The controller targets a 10-15% hourly reduction in 
glucose level to a limit of 5mmol/L. It is achieved with 
a combination of insulin bolus, infusion and/or feed rate 
change. The goal is regulating glucose levels in the 4-
6mmol/L band. Prior to resolving the control inputs, SI 
must be fitted from the prior hours’ data.  
The parameter fitting process is described in [12].  
pG is assumed to be 0.01min-1, a value found by [12] to 
be insensitive across the sampled cohort. The required 
combination of bolus size, insulin infusion rate and/or 
nutritional feed rate to achieve the target glucose level 
in the next hour is determined iteratively using the 
updated SI, and Eqs. (1)-(3). Eqs. (4)-(5) are used to 
determine P(t) based on stepwise fluxes in nutritional 
input rate.    
The patient cohort is from a random selection of 17 
patients from a 201 patient data audit at Christchurch 
Hospital [12] plus 2 patients from a hyperglycaemia 
control clinical trial cohort [13] (see Table 1).  
 
 
Table 1: Long-Term Virtual Trial Patient Cohort 
 
Patient 
number
Medical 
subgroup
Apache II 
score Age Sex Mortality Diabetes
1 Sepsis 17 56 M Type 2
2 Sepsis 24 64 M
24 Other medical 25 47 M Y Type 1
87 Other medical 26 62 F
130 Trauma 11 21 M Type 1
229 Cardiac 15 73 F
289 Cardiac 18 70 M
468 General surgical 32 76 M
484 Other medical 34 30 F
486 General surgical 22 76 F Type 2
519 General surgical 29 69 M Type 2
554 Other medical 26 20 F Type 1
666 Cardiac 8 44 F Type 2
847 Other medical 17 67 F
1016 General surgical 20 37 F Type 2
1025 Pulmonary 36 48 M Type 2
1090 General surgical Unknown 37 F
1099 Pulmonary Unknown 24 M Y
1125 Other medical Unknown 72 F Y  
 
 
This cohort represents a general cross-section of 
ICU population, in medical subgroup, APACHE II 
score, age, sex and mortality (see Table 1).  Ethical 
consent was granted by the Canterbury Ethics 
Committee. Each record has glucose measurements 
every 3h or less, giving adequate data density for 
accurate model fitting.  The average data length is 3.9 
days with a range of 1.4-18.8 days.   
The simulation trials performed use the retrospective 
fitted patient profiles of SI and pG, which simulate the 
physiological patient response with the assumption that 
the parameters are independent of the control inputs 
administered. Thus, a virtual patient response can be 
created for any glucose or insulin inputs. A normally 
distributed error of ±7% is added to the measured 
glucose values to simulate the sensor error of the 
Glucocard™ Test Strip II used clinically. The results are 
compared to the actual hospital data as well as an 
insulin-only control protocol [8].   
 
Results and Discussion 
 
Figures 1-2 show Patient 87 under sliding-scale 
control captured directly from retrospective hospital 
data, the insulin-only protocol from [8], and the variable 
feed and insulin protocol developed here. Tight glucose 
control in the 4-6mmol/L desired band is clear with the 
variable nutrition protocol compared to the other 
protocols. The total insulin administered by the variable 
nutrition protocol is 38.5% less than the insulin-only 
protocol (410.5U versus 667.0U). From the 
retrospective data, the total insulin infused was 248.0U, 
indicating another source of poor control.  
Time spent in the desired 4-6mol/L band was 89% 
versus 21.8% for the insulin-only protocol and 10.7% 
for hospital control. The result for the protocol 
developed was achieved with identical total enteral 
glucose administered to the retrospective patient data 
(1284g versus 1286g). 
    
Figure 1: Patient 87 Simulation Trial Results 
 
Figure 2: Patient 87 SI and Control Input Summary 
 
Compared to the insulin-only protocol, which fed 
the patient at a constant rate, the variable nutrition 
protocol modulated insulin and nutrition inputs as 
driven by the estimated effective insulin sensitivity. 
During periods of high insulin sensitivity, less insulin 
was required, while the standard feed rate was 
maintained.  When the identified insulin sensitivity 
decreased, the feed rate was reduced and insulin 
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increased to maintain blood glucose in the desired band. 
This result shows that the controller recognizes, and can 
compensate for, periods where patient condition 
precludes adequate control with insulin alone. 
Thus, the increase in glucose level between 2500 
and 4500mins with the insulin-only protocol 
corresponds to a period of low insulin sensitivity. With 
no feed rate reduction, increased insulin resistance 
resulted in the glucose level rising to its maximum value 
of 17.3mmol/L, even though the insulin administered 
was identical to other periods in the simulation and at 
saturation limits.  
Glucose levels were normal in the 4-6mmol/L band 
under hospital control only during periods of minimum 
retrospective feed rate between 1600 and 2800mins. 
This case shows that feed rate reduction is the only 
alternative to maintain euglycaemia under these typical 
high insulin resistance levels. 
A summary of the results is shown in Tables 2 and 
3. The variable nutrition and insulin controller increased 
the time spent in the 4-6mmol/L band by 240% 
compared to the insulin-only protocol and 312% versus 
the retrospective data. Time above 6mmol/L is reduced 
by 231% and 237% respectively. No hypoglycaemic 
events occurred in all protocols. 
 
Table 2: Mean Blood Glucose Levels and Percentage 
Time in the 4-6mmol/L Band 
 
Table 4 shows the glucose and insulin prescribed by 
the 3 protocols. The total insulin prescribed by the 
variable insulin and nutrition protocol averages 33% 
less than the insulin-only protocol and 60% more than 
retrospective patient data. The efficiency of the protocol 
developed is further revealed in the total glucose 
administered, which exceeded the retrospective patient 
data by 19.5% on average. The developed protocol 
feeds an average of 718kcal/day of glucose compared to 
the 634kcal/day by the hospital protocol, which also had 
greater variability. Hence, better control was obtained 
with 60% more insulin and 20% more feed. This last 
result also indicates that it is the strategic timing of 
insulin and nutrition delivery, rather than their absolute 
level, which determines tightness of control. 
   
Table 3: Percentage Time Outside the 4-6mmol/L Band  
 
Table 4: Total Insulin and Glucose Administered  
 
Figure 3 summarises these results by plotting 
percentage time in the 4-6mmol/L band versus the log 
mean fitted SI on the x-axis.  The general trend, as 
illustrated by Patient 87, is percentage time-in-band and 
mean blood glucose level decrease with all protocols 
with decreasing mean insulin sensitivity. With insulin 
alone, performance is highly dependent on the patients’ 
effective insulin resistance due to the limitations from 
saturation [8]. The variable feed rate and insulin 
protocol provided tighter blood glucose control across 
the range of observed insulin sensitivities with 
significantly higher time-in-band. The insulin-only 
protocol only reached similar levels at high insulin 
sensitivities, and even then, with significantly more 
administered insulin. For hospital control, greater 
variation in blood glucose control was recorded, as 
expected (R=0.4877, p<0.04), and showed tighter 
control than the insulin-only protocol only at low insulin 
sensitivities, where clinically selected feed reductions 
affected the comparison. 
Variable 
feed and 
insulin
Constant 
feed-rate, 
variable 
insulin
Hospital 
sliding-
scale
Variable 
feed and 
insulin
Constant 
feed-rate, 
variable 
insulin
Hospital 
sliding-
scale
1 6.0 12.1 9.3 66.8 1.6 10.2
2 5.9 9.8 7.8 78.4 0.9 3.6
24 6.6 12.4 12.2 80.1 0.0 0.0
87 5.4 8.4 8.8 89.1 21.8 10.7
130 7.0 13.2 11.2 60.1 0.0 10.3
229 5.4 7.7 7.5 84.6 30.2 15.5
289 5.3 5.5 6.8 80.8 79.8 13.2
468 8.5 10.4 7.4 43.4 0.0 18.5
484 7.5 12.3 11.5 70.0 0.0 0.0
486 6.5 9.4 8.9 60.7 10.6 12.0
519 5.6 7.8 6.3 78.6 51.4 33.9
554 6.0 7.6 6.9 66.5 36.1 20.9
666 7.2 12.4 5.3 35.7 0.0 74.9
847 6.2 6.2 7.3 75.5 75.7 21.7
1016 7.5 9.4 7.2 24.7 0.0 10.7
1025 6.4 7.9 8.0 59.5 41.3 21.0
1090 5.2 5.3 3.9 84.4 82.6 46.8
1099 5.3 5.5 6.5 88.6 82.4 35.8
1125 5.9 7.3 5.4 61.0 21.8 51.8
6.3 9.0 7.8 67.8 28.2 21.7
0.9 2.6 2.2 17.9 31.8 19.3
3.3 7.9 8.3 64.4 82.6 74.9
Percentage of time in 4-6mmol/L 
band (%)Mean Blood Glucose
Controller 
Type
Range
Mean
S. D.
Pa
tie
nt
 N
o.
Variable 
feed and 
insulin
Constant 
feed-rate, 
variable 
insulin
Hospital 
sliding-
scale
Variable 
feed and 
insulin
Constant 
feed-rate, 
variable 
insulin
Hospital 
sliding-
scale
1 0.9 0.0 0.7 32.3 98.4 89.1
2 0.0 0.0 0.0 21.6 99.1 96.4
24 0.0 0.0 0.0 19.9 100.0 100.0
87 0.0 0.0 2.6 10.9 78.2 86.8
130 0.0 0.0 0.0 40.0 100.0 89.7
229 1.7 0.0 0.0 13.8 69.8 84.5
289 0.8 0.0 0.0 18.4 20.3 86.8
468 0.0 0.0 0.0 56.6 100.0 81.6
484 0.0 0.0 0.0 30.0 100.0 100.0
486 3.6 0.0 0.0 35.7 89.4 88.0
519 2.3 0.0 3.4 19.1 48.7 62.7
554 3.9 0.0 16.9 29.6 63.9 62.3
666 0.0 0.0 8.9 64.3 100.0 16.3
847 2.3 0.0 0.0 22.3 24.3 78.3
1016 0.0 0.0 0.0 75.3 100.0 89.3
1025 4.2 0.0 0.7 36.3 58.8 78.3
1090 0.0 0.0 53.3 15.6 17.4 0.0
1099 0.0 1.2 0.0 11.4 16.4 64.2
1125 2.8 0.0 8.6 36.1 78.2 39.5
1.2 0.1 5.0 31.0 71.7 73.4
1.5 0.3 12.5 17.9 31.9 27.5
4.2 1.2 53.3 64.4 83.6 100.0
Percentage of time below 4-
6mmol/L band (%)
Percentage of time above 4-
6mmol/L band (%)
Controller 
Type
Range
Mean
S. D.
Pa
tie
nt
 N
o.
Variable 
feed and 
insulin
Constant 
feed-rate, 
variable 
insulin
Hospital 
sliding-
scale
Variable 
feed and 
insulin
Constant 
feed-rate, 
variable 
insulin
Hospital 
sliding-
scale
Constant feed-
rate, variable 
insulin
Hospital 
sliding-
scale
1 1488 2042 1125 2720 5355 2606 51 49
2 370 486 213 931 1285 672 72 52
24 127 215 183 305 583 577 52 99
87 411 667 248 1284 1833 1286 70 70
130 97 143 111 188 393 143 48 36
229 567 1032 232 2564 2868 1940 89 68
289 88 108 42 440 476 312 92 65
468 58 77 41 176 238 264 74 111
484 125 172 200 312 476 492 66 103
486 123 162 82 307 464 296 66 64
519 706 1234 221 2836 3499 1856 81 53
554 134 198 90 508 643 348 79 54
666 150 169 61 203 464 62 44 13
847 60 109 41 426 441 407 97 92
1016 159 166 62 239 464 166 51 36
1025 101 163 59 412 476 370 86 78
1090 99 135 39 415 464 125 89 27
1099 64 77 51 440 464 480 95 103
1125 104 156 41 287 476 141 60 30
264.7 395.1 165.3 789.2 1124.4 660.2 71.8 63.4
347.9 515.9 244.6 894.5 1359.7 722.5 17.3 28.7
1430.1 1964.6 1085.5 2659.2 5117.0 2543.5 53.0 97.4
Percentage of maximum 
glucose (1000kcal/day) 
administered (%)
Total insulin administered (U) Total glucose administered (g)
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tie
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Figure 3: Insulin Sensitivity, SI, versus Time in the 4-
6mmol/L Band 
 
It is important to note that most, or all, of the 
clinical, hospital reductions in feed rate were not 
performed for hyperglycaemia.  Similarly, the insulin-
only protocol had a conservative 1000kcal/day constant 
feed rate to manage, showing more efficient insulin 
delivery than hospital control despite this handicap.  
Hence, some improvement could be expected in the 
insulin-only protocol results.   
 
Conclusions 
 
The long-term simulated trials conducted across a 
wide ICU population showed that glucose management 
with intensive insulin therapy and feed rate modulation 
results not only in a reduction in absolute glucose levels, 
but in the severity of fluctuation in glucose levels. A 
312% increase in time spent in the desired 4-6mmol/L 
band is achieved compared to using a constant feed rate 
and the same insulin control. Furthermore, the results 
are achieved with just 60% more insulin and, 
surprisingly, 20% more glucose nutrition compared to 
retrospective data. Note that the cohort selected 
exhibited wide ranging, time-varying patient condition 
with regard to insulin resistance. The variable insulin 
and feed control protocol developed exhibited far higher 
robustness to inter-patient variability and time-varying 
physiological condition than the insulin-only protocol, 
enabling more stable regulatory performance. 
Clinically, these results indicate the potential in both 
simulation and shorter, pilot clinical trials to reduce ICU 
mortality.  
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